• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    5/27/24 4:31:32 PM ET
    $ATHE
    $DHAI
    $ICAD
    $KTRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ATHE alert in real time by email

    Gainers

    • Sharps Technology (NASDAQ:STSS) stock increased by 87.0% to $0.4 during Monday's after-market session. The company's market cap stands at $6.2 million.
    • MorphoSys (NASDAQ:MOR) stock increased by 25.94% to $23.35. The market value of their outstanding shares is at $3.5 billion.
    • Kintara Therapeutics (NASDAQ:KTRA) shares increased by 12.49% to $0.19. The market value of their outstanding shares is at $10.4 million.
    • Mustang Bio (NASDAQ:MBIO) stock moved upwards by 11.91% to $0.23. The market value of their outstanding shares is at $2.9 million.
    • icad (NASDAQ:ICAD) shares moved upwards by 10.75% to $1.75. The market value of their outstanding shares is at $46.4 million.
    • Renalytix (NASDAQ:RNLX) shares moved upwards by 9.3% to $0.46. The market value of their outstanding shares is at $35.8 million.

    Losers

    • DIH Holding US (NASDAQ:DHAI) stock decreased by 24.4% to $1.21 during Monday's after-market session. The company's market cap stands at $49.0 million.
    • Innovative Eyewear (NASDAQ:LUCY) shares decreased by 14.04% to $0.84. The company's market cap stands at $14.7 million.
    • Scinai Immunotherapeutics (NASDAQ:SCNI) stock decreased by 12.99% to $3.62. The company's market cap stands at $2.1 million.
    • Alterity Therapeutics (NASDAQ:ATHE) shares decreased by 9.46% to $1.82. The market value of their outstanding shares is at $15.8 million.
    • Onconetix (NASDAQ:ONCO) shares declined by 8.86% to $0.17. The company's market cap stands at $3.7 million.
    • SCWorx (NASDAQ:WORX) stock decreased by 8.59% to $1.81. The company's market cap stands at $2.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATHE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATHE
    $DHAI
    $ICAD
    $KTRA

    CompanyDatePrice TargetRatingAnalyst
    iCAD Inc.
    $ICAD
    4/17/2025Buy → Neutral
    BTIG Research
    iCAD Inc.
    $ICAD
    4/17/2025Buy → Hold
    Laidlaw
    Alterity Therapeutics Limited
    $ATHE
    2/3/2025Speculative Buy → Hold
    The Benchmark Company
    Alterity Therapeutics Limited
    $ATHE
    12/12/2024$8.00Buy
    Maxim Group
    MorphoSys AG
    $MOR
    3/14/2024Overweight → Equal Weight
    Wells Fargo
    MorphoSys AG
    $MOR
    1/16/2024$9.19 → $10.40Overweight → Equal-Weight
    Morgan Stanley
    MorphoSys AG
    $MOR
    10/13/2023$3.70 → $9.19Underweight → Overweight
    Morgan Stanley
    MorphoSys AG
    $MOR
    9/15/2023$3.50 → $9.25Sell → Neutral
    Goldman
    More analyst ratings

    $ATHE
    $DHAI
    $ICAD
    $KTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider White David Allan

    3 - Onconetix, Inc. (0001782107) (Issuer)

    3/27/26 4:10:42 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Dorf Sammy

    3 - Onconetix, Inc. (0001782107) (Issuer)

    3/27/26 4:10:29 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Mark Elad

    3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

    3/26/26 8:41:16 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATHE
    $DHAI
    $ICAD
    $KTRA
    SEC Filings

    View All

    SEC Form 425 filed by Onconetix Inc.

    425 - Onconetix, Inc. (0001782107) (Subject)

    4/2/26 8:31:13 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 20-F filed by Scinai Immunotherapeutics Ltd.

    20-F - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

    4/1/26 7:36:13 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Alterity Therapeutics Limited

    6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)

    4/1/26 6:10:30 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    $DHAI
    $ICAD
    $KTRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Gross Harrison R. bought $1,980 worth of shares (1,500 units at $1.32), increasing direct ownership by 12% to 13,733 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/22/26 11:29:05 AM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Chief Financial Officer Gayle Oswald bought $1,669 worth of shares (1,000 units at $1.67), increasing direct ownership by 54% to 2,865 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/15/26 5:00:07 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Chief Executive Officer Gross Harrison R. bought $2,400 worth of shares (1,500 units at $1.60), increasing direct ownership by 14% to 12,233 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/12/26 5:00:39 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    $ATHE
    $DHAI
    $ICAD
    $KTRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update

    Realbotix Announces Expected Delivery of 19 Robots in March, April, and May 2026 as it Scales Production Capacity; Onconetix recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a subsidiary of Realbotix Corp. CINCINNATI, Ohio, April 02, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC ("Realbotix"), the target of Onconetix's previously announced pending acquisition. On April 1, 2026, Realbotix announced that it expects to deliver 19 previously ordered robots and corresponding AI implementations for months of March, April, and

    4/2/26 8:30:00 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

    JERUSALEM, April 1, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business model designed to combine therapeutic innovation with revenue-generating drug development and manufacturing services, today reported financial results for the year ended December 31, 2025. Corporate and Financial HighlightsCDMO revenues doubled year-over-year to $1.3 million, reflecting continued commercial traction and execution of development and manufacturing programsExpanded CDMO platform post year-end through the acquisition of Recipharm Israel and entry into a strategic commercial collaboration with Reciph

    4/1/26 7:35:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors

    Experienced Leadership Team Positioned to Execute Pending Transformative Acquisition of Realbotix LLC and Drive Long-Term Shareholder Value CINCINNATI, Ohio, March 31, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") today announced the appointment of David White as Chief Executive Officer, effective March 18, 2026, and the appointment of Sammy Dorf as a member of the Company's Board of Directors and the Audit Committee, effective March 19, 2026. Karina Fedasz, the Company's outgoing Interim Chief Executive Officer, will continue to serve as its Interim Chief Financial Officer. These appointments reflect the Company's commitment to assembling experien

    3/31/26 8:30:00 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    $DHAI
    $ICAD
    $KTRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    iCAD downgraded by BTIG Research

    BTIG Research downgraded iCAD from Buy to Neutral

    4/17/25 8:29:51 AM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    iCAD downgraded by Laidlaw

    Laidlaw downgraded iCAD from Buy to Hold

    4/17/25 8:29:51 AM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    Alterity Therapeutics downgraded by The Benchmark Company

    The Benchmark Company downgraded Alterity Therapeutics from Speculative Buy to Hold

    2/3/25 7:02:17 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    $DHAI
    $ICAD
    $KTRA
    Leadership Updates

    Live Leadership Updates

    View All

    Innovative Eyewear, Inc. Announces New Smart Safety Glasses and Rx Safety Partner

    MIAMI, March 31, 2026 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ: LUCY; LUCYW), the developer & manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, is pleased to announce the launch of the new Lucyd Armor® Vantage style. The new smart safety frame is fully certified for workplace use under US, Canadian and European standards. The frame will debut on March 31, 2026 at the National Hardware Show: Concept to Commerce event in Las Vegas. The frame will launch on the Company's website as well as with its new premier reseller for the safety channel, Ocusafe.com.

    3/31/26 8:00:00 AM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor

    MELBOURNE, Australia and SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Daniel O. Claassen, M.D., M.S., was appointed Chief Medical Advisor and will begin his role in March 2026. As a tenured professor, Dr. Claassen will also retain his academic appointment at Vanderbilt University Medical Center. Dr. Claassen is a board-certified neurologist and internationally recognized expert in neurodegenerative diseases, with more than two decades of clinical and translational research in mov

    3/4/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

    − Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter.Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers to explore non-dilutive pathways to fund Phase 3 development.Board and executive leadership strengthened to support Alterity through its next stage of clinical development, partnering and comme

    1/30/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    $DHAI
    $ICAD
    $KTRA
    Financials

    Live finance-specific insights

    View All

    Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

    JERUSALEM, April 1, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business model designed to combine therapeutic innovation with revenue-generating drug development and manufacturing services, today reported financial results for the year ended December 31, 2025. Corporate and Financial HighlightsCDMO revenues doubled year-over-year to $1.3 million, reflecting continued commercial traction and execution of development and manufacturing programsExpanded CDMO platform post year-end through the acquisition of Recipharm Israel and entry into a strategic commercial collaboration with Reciph

    4/1/26 7:35:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Innovative Eyewear Inc. Reports Full Year 2025 Financial Results

    Revenue increased 63% over prior year Gross Profit Margins increased by 8 percentage points despite tariff headwindsMIAMI, March 25, 2026 /PRNewswire/ -- Innovative Eyewear Inc., (NASDAQ:LUCY, LUCYW)), the developer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its full year 2025 financial results. Net revenue for the year ended December 31, 2025 was approximately $2.67 million, an increase of $1.03 million or 63% from the year ended December 31, 2024. This strong year-over-year revenue growth was primarily driven by

    3/25/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Innovative Eyewear, Inc. Announces Q4 and Full Year 2025 Earnings Conference Call

    MIAMI, March 10, 2026 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ: LUCY; LUCYW), the developer & manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its upcoming earnings conference call to share the Company's key operational and financial results for the fiscal year ended December 31, 2025. Earnings Call DetailsDate: Tuesday, March 31, 2026Time: 12:00 PM ETParticipant Listening OptionsInterested participants can join the event by using the dial-in numbers, or by cl

    3/10/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    $ATHE
    $DHAI
    $ICAD
    $KTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    11/26/24 5:02:01 PM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by DIH Holdings US Inc.

    SC 13G/A - DIH HOLDING US, INC. (0001883788) (Subject)

    11/14/24 6:07:49 PM ET
    $DHAI
    Medical/Dental Instruments
    Health Care